Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Liquid Molecular Testing Panel in the Community Setting ("DINOSAur II")

Status unconfirmed

Conditions studied: Stage III Solid Tumors, Stage IV Solid Tumors

In brief

To prospectively identify cancer patients whose tumors express specific molecular markers targeted by therapeutic agents from a comprehensive l i q u i d molecular test, for the purpose of selecting the most clinically appropriate treatment in a pragmatic two arm trial.

Key facts

Study ID

NCT05703243

Run by

Glendale Adventist Medical Center d/b/a Adventist Health Glendale

People needed

572

Starts

2023-02-01

Expected to finish

2025-01-01

Last updated by the study team

2023-03-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who have given informed consent in accordance with the methods and procedures of this study
• Diagnosis of cancer (stage 3 and stage 4; solid tumors only) requiring medical care
• Patients who have not received treatment related to his/her cancer
• Patients who are willing to sign a release of medical records to the research team
• Male and female patients ≥18 years of age
• Patients under oncology care
• Sufficient clinical status for collection of blood sample within usual care

You may not qualify if…

• Patients considered minors in the jurisdiction where the protocol is conducted
• Patients who are prisoners and pregnant women
• Patients who cannot provide consent and did not sign a power of attorney

Where it is running

• Adventist Health Glendale — Glendale, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.